Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Renoxitin 2g Powder for solution for injection or Infusion

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Cefoxitin sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Cefoxitin sodium
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Renoxitin is a beta-lactam antibiotic in the group of the second-generation cephalosporins. This medicine is indicated in adults and in adolescents for the treatment of infections when known or suspected to be caused by pathogens susceptible to cefoxitin. Renoxitin is indicated for: • complicated urinary tract infections • pyelonephritis Cefoxitin may have utility notably in intra-abdominal infections and some gynaecological infections. 2.

What you need to know before you take it

e Renoxitin

Do not use Renoxitin: if you are allergic to cefoxitin, to any other cephalosporin antibiotics or any of the other ingredients of this medicine (listed in section 6). if you have ever had a severe allergic (hypersensitive) reaction (e.g., severe skin peeling; swelling of the face, hands, feet, lips, tongue or throat; or difficulty swallowing or breathing) to any other type of betalactam antibiotic (penicillins, monobactams and carbapenems). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Renoxitin. Allergic reactions Any signs of an allergic reaction (rash, itching…) during treatment should be immediately reported to your doctor. If a severe, sudden allergic reactions happens, the administration of Renoxitin will have to be stopped. Before you start this treatment, tell your doctor if you have ever developed hives or another type of rash, itching, Quincke's oedema (sudden swelling of the face and neck caused by an allergic reaction) during previous treatment with antibiotics.

2

Diarrhoea The occurrence of diarrhoea during antibiotic treatment should not be treated without medical advice. Diarrhoea may develop while you are taking antibiotics, including cefoxitin, or after you have stopped taking them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, contact your doctor immediately, as this can be life-threatening. Do not take medicines that stop or slow down bowel movements. In case of doubt, talk to your doctor or pharmacist. Neurological disorders As with all antibiotics belonging to this therapeutic class, the administration of this medicinal product may lead to a risk of encephalopathy (which may result in confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or kidney dysfunction. If any of these appear, consult your doctor or pharmacist immediately (see sections 3 and 4). Kidney function Inform your doctor if you have kidney disease, because your dose may need to be adjusted. If you are taking other medicines that are harmful for your kidneys or if you use diuretics (water pills), your doctor will monitor your kidney function. Laboratory tests Some laboratory test results may be altered while you take this medicine. Other medicines and Renoxitin Tell your doctor if you are using, have recently used or might use any other medicines. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Pregnancy Renoxitin should be used during pregnancy only under medical advice. If you discover that you are pregnant while taking Renoxitin, consult your doctor who is the only person who can judge whether the drug should be continued. Breast-feeding Stop breast-feeding while you are using this medicine to avoid any allergic reactions in your baby. Driving and using machines Renoxitin has a major influence on the ability to drive and use machines especially because of the possible occurrence of encephalopathy (see sections 3 and 4). Renoxitin contains sodium. This medicinal product contains 50 mg of sodium (main component of cooking/table salt) per g. This is equivalent to 2,5% of the recommended maximum daily dietary intake of sodium for an adult. This should be taken into consideration if you are on a controlled-sodium diet.

3.

How to use Renoxitin

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor or other Healthcare professional will give you this medicine into one of your veins. Recommended dose

3

Your doctor will decide the dose that you need each day and how often the injections/infusions should be administered per day. The recommended dose may be: Adults and adolescents: 2g every 4- 6 hours to a maximum of 12g/ day. Patients with kidney problems If you have a kidney problem, your doctor may change your dose. Use in Children There are insufficient data to recommend a posology in children aged up to 11 years.

How to take it

Renoxitin Cefoxitin may be administered by slow intravenous injection over a period of 3 to 5 minutes. A solution of this medicinal product may also be administered by continuous intravenous infusion. For instructions on reconstitution and dilution of the medicinal product before administration, see information intended for Healthcare professionals. If you use more Renoxitin than you should As with all antibiotics belonging to this therapeutic class, the administration of this medicinal product may lead to a risk of encephalopathy (which may result in confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or kidney dysfunction. If any of these appear, consult your doctor or pharmacist immediately (see sections 2 and 4). If you forget to use Renoxitin Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Not known (the frequency is not known):

  • Local reactions;
  • Local inflammation of the vein with clot formation that may obstruct intravenous administration
  • Fever, allergic reactions, Quincke's oedema (sudden swelling of the face and neck caused by allergies), interstitial nephritis (kidney disease).
  • Rash that look like that caused by stinging nettles (urticaria), itching and rarely severe skin lesions.
  • Nausea, vomiting, diarrhoea; rare cases of pseudomembranous colitis (bowel disease with diarrhoea and abdominal pain) (see Warnings and precautions).
  • Blood abnormalities (eosinophilia, leukopenia, neutropenia, agranulocytosis, anaemia, thrombocytopenia, medullary hypoplasia), characterised by elevation of certain blood components (eosinophils) or a decrease in certain blood components which could result in unexplained fever, nosebleeds or bleeding gums, paleness or extreme fatigue. Contact your doctor as soon as possible.
  • Increased levels of certain liver enzymes – transient elevation of transaminases (AST, ALT), lactate dehydrogenase, alkaline phosphatase.
  • Kidney impairment, especially when certain other medicines are used at the same time (aminoglycosides, diuretics), which could result in abnormal blood test results (elevated creatinine and/or blood urea nitrate).
  • Myasthenia gravis exacerbation (muscle disease).

4

–

Serious neurological disorders known as encephalopathy (which may result in confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of high doses or kidney dysfunction (see sections 2 and 3).

Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App. By reporting side effects, you can help provide more information on the safety of this medicine. 5.

How to store it

Renoxitin

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. After reconstitution: Chemical and physical in-use stability has been demonstrated for 8 hours at 25°C and 2-8°C with Water for Injections. From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions are the responsibility of the user. After dilution of the reconstituted solution with the solvents: Do not refrigerate. Chemical and physical in-use stability has been demonstrated for 4 hours at 25 °C. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of user. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Renoxitin contains –

The active substance is cefoxitin sodium. Each vial contains 1.0515 g of cefoxitin sodium equivalent to 1000 mg of cefoxitin. Each vial contains 2.103 g of cefoxitin sodium equivalent to 2000 mg of cefoxitin.

What Renoxitin looks like and contents of the pack Renoxitin is a white or almost white powder. Renoxitin is supplied in vials containing 1g or 2g of cefoxitin as the sodium salt, closed with chlorobutyl rubber stopper and sealed with an aluminium capsule with polypropylene flip-off. Renoxitin 1g Powder for solution for injection/infusion is available in packs of 1, 5, 10, 20, 25, 50 and 100 vials. Renoxitin 2g Powder for solution for injection/infusion is available in packs of 1, 5, 10, 20, 25, 50 and 100 vials. Not all pack sizes will be marketed. 5

Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Renascience Pharma Limited The Urban Building Second Floor, 3-9 Albert Street, Slough, Berkshire, SL1 2BE, United Kingdom Manufacturer LDP- Laboratorios TORLAN, S.A. Ctra de Barcelona, 135 B 08290 Cerdanyola del Valles Barcelona – Spain This leaflet was last revised in 05/2025

————————————————————————————————————————–ADVICE/MEDICAL EDUCATION What should you know about antibiotics? Antibiotics are effective against infections caused by bacteria. They do not work against infections caused by viruses. Also, your doctor chose to prescribe this antibiotic for you because it suits your particular case and your current illness. Some bacteria have the ability to survive and reproduce despite the action of an antibiotic. This phenomenon is known as resistance: it inactivates certain antibiotic treatments. Resistance is the result of abusive or inappropriate use of antibiotics. You may promote the development of resistant bacteria and therefore delay your recovery or even inactivate this medicine, if you do not:

  • take the dose prescribed for you,
  • take it as often as prescribed,
  • complete the whole course of treatment. Therefore, to preserve the efficacy of this medication: 1. Do not use an antibiotic unless it has been prescribed by your doctor. 2. Take it exactly as prescribed. 3. Do not reuse an antibiotic without a prescription, even if you think you are treating an illness that appears to be similar. 4. Never give your antibiotic to another person, because it may not be appropriate for that person's illness. 5. Once your treatment is complete, return to your pharmacist any opened boxes so that they can be discarded correctly and appropriately. The following information is intended for healthcare professionals only: Special precautions for disposal and other handling

6

Cefoxitin may be reconstituted with 10 ml water for injections. Immediately after reconstitution, this Cefoxitin solution can be also added to 40 ml of the following solutions, frequently used in infusion(1g or 2g into 50 ml solution, corresponding to 20 to 40mg/ml):

  • sodium chloride 0.9%,
  • glucose 5% or 10%,
  • mixed solution of glucose 5% and sodium chloride 0.9%,
  • glucose 5% buffered with sodium bicarbonate 0.02%,
  • glucose 5% supplemented with saline solution 0.2% or 0.45%,
  • Ringer's Lactate solution,
  • mixed solution of glucose 5% and Ringer Lactate,
  • mixed solution of fructose 5% or 10% in water for injections,
  • fructose 10% solution in saline solution,
  • Sodium lactate solution at M/6. This medicine may be given together with other antibiotics (intravenously with separate syringes or infusions). When this medicine is administered at the same time as another antibiotic, it is important that the antibiotics are not mixed in the same syringe or infusion. Reconstitution Renoxitin should be reconstituted with water for injections: 1 g is soluble in 2 ml. Although, Renoxitin is very soluble, for intravenous use it is preferable to add 10 ml of water for injections to the 1 g vial or to the 2 g vial. It should be shaken to dissolve and then withdraw the entire contents of the vial into a syringe. Dilution The reconstituted solution should be diluted with the solvents mentioned above in section 6.6: add around 40 ml of the solvent to the reconstituted solution in order to reach a total volume of 50 ml. The product should be used immediately after reconstitution/dilution. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7

Frequently asked questions about Renoxitin 2g Powder for solution for injection or Infusion

How do I take Renoxitin 2g Powder for solution for injection or Infusion?

Renoxitin 2g Powder for solution for injection or Infusion comes as injection containing 2g. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Renoxitin 2g Powder for solution for injection or Infusion?

The active substance in Renoxitin 2g Powder for solution for injection or Infusion is cefoxitin sodium.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Renoxitin 2g Powder for solution for injection or Infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Renoxitin 2g Powder for solution for injection or Infusion without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Cefoxitin sodium (2 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Renoxitin is indicated in adults and adolescents,

Cefoxitin should only be prescribed after consultation with physicians with appropriate expertise in the treatment of infectious diseases.

Cefoxitin may be used in the following infections when known or suspected to be caused by pathogens susceptible to cefoxitin and for which other, more commonly prescribed antibacterial agents are not appropriate.

Renoxitin is indicated for:

• complicated urinary tract infections

• pyelonephritis

Cefoxitin may have utility notably in intra- abdominal infections and some gynaecological infections. Please see section 4.4 for special warnings and precautions.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2. Posology and method of administration

Posology

There are very limited clinical safety and efficacy data supporting the dose of cefoxitin. Therapeutic guidelines should be adhered to.

Based on these very limited clinical data and some supporting pharmacokinetic/ pharmacodynamic data, the following may be appropriate:

Adults and adolescents:

2g every 4- 6 hours to a maximum of 12g/ day.

Renal impairment

There are extremely little data on the administration of cefoxitin in patients with renal impairment. Great caution is advised when cefoxitin is administered to these patients. In adults with renal impairment, an initial loading dose of 2 g can be administered. After the loading dose, the following recommendations can be used as guide for maintenance treatment:

Creatinine clearance (mL/min)

Dose

Frequency

50 - 30

2 g

Every 8 - 12 hours

29 - 10*

2 g

Every 12 - 24 hours

* In patients on haemodialysis, the loading dose of 2 g should be given after each haemodialysis, and the maintenance treatment should be given as indicated in the table above.

Paediatric population

There are insufficient data to recommend a posology in children aged up to 11 years.

Method of administration

Cefoxitin may be administered by slow intravenous injection over a period of 3 to 5 minutes.

A solution of this medicinal product may also be administered by continuous intravenous infusion.

For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.

4.3. Contraindications

Hypersensitivity to the active substance, to any other cephalosporin antibiotics or to any of the excipients listed in section 6.1.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

4.4. Special warnings and precautions for use

Hypersensitivity reactions

As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefoxitin must be discontinued immediately and adequate emergency measures must be initiated.

Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefoxitin, to other cephalosporins or to any other type of beta-lactam antibacterial agent. Caution should be used if cefoxitin is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.

Clostridium difficile-associated diarrhoea

Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents and may occur with Cefoxitin (see section 4.8). These types of infection may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of the antibiotic. In such circumstances, the discontinuation of therapy with cefoxitin and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.

Non-susceptible microorganisms

Prolonged use may result in the overgrowth of non-susceptible micro-organisms, which may require interruption of treatment or other appropriate measures.

Risk of encephalopathy

Beta-lactam antibiotics exposes to a risk of encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or reduced renal function.

Impaired renal function

In patients with renal impairment, dosage adjustment should be based on the creatinine clearance and serum creatinine (see section 4.2).

Concurrent treatment with diuretics or aminoglycosides

Renal function should be monitored during treatment if cefoxitin is given in combination with other potentially nephrotoxic antibiotics (especially aminoglycosides), or with furosemide or etacrynic acid diuretics.

Bacterial meningitis

The use of cefoxitin in the treatment of meningitis is not substantiated by appropriate data. Therefore, cefoxitin is not indicated for the treatment of meningitis.

Important information about excipients

Renoxitin contains sodium.

This medicinal product contains 2.17 mmol (or 50 mg) of sodium, per g equivalent to 2,5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Interference with laboratory tests

• Coombs test: false-positive results have been observed during treatment with cephalosporins. This may also occur in patients treated with cefoxitin.

• Glycosuria: false-positive results may be observed with reduction substances, however, no interaction has been observed with enzymatic methods.

• Jaffe (picric acid) serum creatinine test may show falsely high creatinine values. This may occur if cefoxitin serum concentrations exceed 100 mcg/ml.

Do not perform this assay on serum samples taken less than 2 hours after administration of Renoxitin.

• Urinary 17-hydroxy-corticosteroid: Porter Silber reaction may give moderate, falsely increased results in patients with high urinary concentrations of cefoxitin.

4.5. Interaction with other medicinal products and other forms of interaction

Problems specific to uncontrolled INR

There are numerous reports of potentiation of oral anticoagulant activity in patients on antibiotic therapy. The infectious or inflammatory disease background, the age and general condition of the patient appear to be risk factors. In these circumstances, it can be difficult to establish whether the infectious pathology or its treatment has caused the uncontrolled INR. However, certain classes of antibiotics are more involved, including fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and certain cephalosporins.

4.6. Fertility, pregnancy and lactation

Pregnancy

Animal studies have not shown evidence of a teratogenic effect. As teratogenic effects have not been observed in animals, malformations are not expected in humans. To date, substances that have been found to cause malformations in humans have been shown to be teratogenic in animals during well-controlled studies on two animal species.

A large amount of clinical data on pregnant women indicate no malformative nor feto/neonatal toxicity of cefoxitin. Nevertheless, epidemiological studies would be required to verify the absence of risk.

Renoxitin should therefore only be used during pregnancy if clinically needed.

Breast-feeding

Cefoxitin is excreted in human milk.

Breast-feeding should be discontinued during administration of Renoxitin to prevent any allergic reactions in the infant.

4.7. Effects on ability to drive and use machines

Renoxitin has a major influence on the ability to drive and use machines especially because of the possible occurrence of encephalopathy (see sections 4.4, 4.8 and 4.9).

4.8. Undesirable effects

Undesirable effects are classified by frequency and system organ class. The following terminologies have been used in order to classify the occurrence of undesirable effects: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1.000 to <1/100), rare (≥1/10.000 to <1/1.000), very rare (<1/10.000), not known (cannot be estimated from the available data).

System organ class

Frequency of undesirable effects

Frequency not known

Immune system disorders

Anaphylactic reaction

Blood and lymphatic system disorders

Eosinophilia

Leukopenia

Neutropenia (agranulocytosis)

Anaemia (including haemolytic anaemia)

Thrombocytopenia

Bone marrow failure

Vascular disorders

Local thrombophlebitis after intravenous administration

Gastrointestinal disorders

Nausea

Vomiting

Diarrhoea

Pseudomembranous colitis

Nervous system disorders

Encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements)*

Hepatobiliary disorders

Transaminases increased

Blood lactate dehydrogenase increased

Blood alkaline phosphatase increased

Skin and subcutaneous tissue disorders

Rash

Urticaria

Pruritus

Toxic epidermal necrolysis

Angioedema

Musculoskeletal and connective tissue disorders

Myasthenia gravis exacerbation

Renal and urinary disorders

Nephritis interstitial

Blood creatinine increased and/or BUN increased (especially in combination therapy with aminoglycosides and loop diuretics)

Severe renal impairment

General disorders and administration site conditions

Pyrexia

Local reaction

* Βeta-lactam antibiotics expose to a risk of encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or reduced renal function.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in appendix V.

4.9. Overdose

Beta-lactam antibiotics exposes to a risk of encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or reduced renal function.

💬 Ask about this leaflet

Ask anything about Renoxitin 2g Powder for solution for injection or Infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →